Cultivation, manufacturing and GMP | Medicinal Cannabis NZ Guide

Cultivation, manufacturing and GMP: What quality system separates a legal medicinal cannabis product from an illegal one in New Zealand

The answer is the Medicinal Cannabis Scheme, run by the Ministry of Health through the Medicinal Cannabis Agency (MCA) within Medsafe. The scheme does not legalise cannabis generally. It creates a controlled route: a medical practitioner prescribes an approved item, a pharmacist dispenses it, and every item must meet Good Manufacturing Practice (GMP) standards. The legal item is a manufactured pharmaceutical. Raw plant material, even if labelled “medicinal”, is only legal when it is a prescribed pharmaceutical dispensed through a pharmacy.

In New Zealand, the only legal dried cannabis flower is a GMP-manufactured pharmaceutical dispensed through a pharmacy for vaporisation, not smoking, and no patient may cultivate it at home regardless of prescription status.

The legal framework

New Zealand’s medicinal cannabis regime is set out in the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. The Medicinal Cannabis Agency (MCA) sits within Medsafe and administers the scheme. The framework creates a controlled route for patients who have a prescription from a medical practitioner. Items must meet GMP standards and be approved before they can be prescribed and dispensed.

Key legal boundaries, effective since 1 April 2020 when the product standards came into force:

A prescription from a medical practitioner is mandatory. The Misuse of Drugs Act 1975 and the Misuse of Drugs Regulations 1977 govern the route. A doctor may prescribe a controlled drug such as THC-containing cannabis under Section 22A of the Misuse of Drugs Amendment Act 2018.
The legal item is a manufactured pharmaceutical. Raw plant material, when prescribed, is dispensed through a pharmacy as a manufactured item, not sold in a dispensary or café. Smoking raw flower is not covered by the scheme.
Items must meet GMP and be approved by Medsafe under the Medicinal Cannabis Scheme.
No self-referral, no “cannabis clinic” bypass, no over-the-counter sale.
Medicinal cannabis is a controlled drug, not a general licence.

Regulatory bodies and sources

Medicinal Cannabis Scheme: Established by the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, fully operational 1 April 2020.
Medsafe: The New Zealand Medicines and Medical Devices Safety Authority, which approves quality standards and product notifications.
Medicinal Cannabis Agency (MCA): Part of Medsafe, manages licensing, product approvals and compliance.
Prescription: Issued by an authorised prescriber; a standard prescription is not valid for cannabis.
Misuse of Drugs Act 1975: Governs controlled drugs; medicinal cannabis items are Schedule 1 or 2 depending on THC content.
NZ Formulary: Contains official prescribing guidance, including cannabis product monographs.

What “medicinal cannabis” means under New Zealand law

Under the Misuse of Drugs Act 1975, cannabis remains a controlled drug. The Medicinal Cannabis Scheme creates a narrow, regulated exception: a medical practitioner can prescribe a cannabis item that has been manufactured to pharmaceutical standards and approved for supply. The scheme came into force on 1 April 2020. It does not legalise recreational use, and it does not allow a patient to grow, buy or smoke raw plant material outside a prescription route.

The key legal boundary is the item, not the plant. A “medicinal cannabis product” must be a pharmaceutical-grade preparation that meets GMP standards and has been notified to the Ministry of Health. Raw dried flower can be prescribed and dispensed through a pharmacy, but it is still a manufactured, quality-assured item, not a loose herb. Smoking is not an approved administration route; the Ministry of Health’s guidance is clear that vaporisation is the inhaled route, not smoking (New Zealand Ministry of Health, 2023).

How the framework changed in 2020

The Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 came into force on 1 April 2020, creating the Medicinal Cannabis Scheme. A medical practitioner can prescribe a CBD or THC item that meets GMP and Ministry of Health approval. The Ministry of Health has published the minimum quality standards, and the MCA issues licences and product approvals. Medsafe maintains the public list of approved items, and the NZ Formulary lists cannabis monographs for prescribers.

Cultivation is licensed, not personal

Under the scheme, the Ministry of Health licenses growers and manufacturers under the Misuse of Drugs Act. A licence is required for any activity involving controlled drugs, including cultivation, production, manufacture and supply. The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 specify that only licensed persons may cultivate medicinal cannabis; there is no provision for home cultivation by patients, even with a prescription. The MCA within Medsafe issues these licences and inspects facilities to ensure GMP compliance.

The three regulated categories

Pharmaceutical-grade items

These are full-extract or isolate preparations manufactured under GMP. They include oral solutions, capsules, sublingual sprays and dried flower for vaporisation. Every batch undergoes quality control testing for potency, purity and stability before release.

Raw material (dried flower)

Dried cannabis flower is legal only when prescribed and dispensed through a pharmacy as a manufactured pharmaceutical. It is intended for vaporisation, not smoking. The flower must meet GMP standards for microbial limits, heavy metals, pesticides and cannabinoid content.

CBD-only items

Items containing cannabidiol with minimal or no THC may fall under different scheduling, but they still require Medsafe approval and must meet quality standards if supplied as medicinal items. Over-the-counter CBD items are not part of the Medicinal Cannabis Scheme unless they hold a product notification.

How a prescription works in practice

A patient cannot self-refer. A medical practitioner must assess the patient and decide whether a medicinal cannabis item is clinically appropriate. The prescriber writes a prescription for a specific approved item, which the patient takes to a pharmacy. The pharmacist dispenses the manufactured pharmaceutical, not a loose plant substance. No dispensing occurs through a café, dispensary or online store without a pharmacy licence.

What to do before a prescription is written

Confirm the prescriber is a registered medical practitioner authorised to prescribe controlled drugs.
Check that the proposed item appears on Medsafe’s list of approved medicinal cannabis items.
Ask the prescriber which administration route is intended (oral, sublingual or vaporised flower) and confirm that smoking is not approved.
Verify the pharmacy is licensed to dispense controlled drugs.
Request the product information sheet and check the batch number and expiry date when you collect the item.

What GMP means in practice

Good Manufacturing Practice certification is not a paper exercise. It requires:

Facility certification: Manufacturing sites are inspected by Medsafe or an recognised international regulator to confirm they meet pharmaceutical standards.
Quality control: Every batch is tested for cannabinoid potency, terpene profile (where claimed), residual solvents, pesticides, heavy metals and microbial contamination.
Stability testing: Manufacturers must provide data showing the item remains within specification for its shelf life.
Traceability: Each unit can be traced back to its batch, cultivation source and manufacturing date.

The MCA monitors compliance and can suspend or revoke licences.

What a product label must tell you

A compliant label includes:

The product name and active ingredient (e.g., THC, CBD) with concentration per unit.
The batch number and expiry date.
The name of the licence holder or sponsor.
Storage conditions and administration instructions.
A statement that the item is a controlled drug and must be kept out of reach of others.

A label does not guarantee the item is legal. Always cross-check the item against the Medsafe public list.

Decision rule: flower, oil or capsule?

Use this rule when discussing options with your prescriber:

Choose an oral solution or capsule if you need consistent, longer-duration dosing and can wait 30 to 90 minutes for onset.
Choose dried flower for vaporisation if you need rapid onset and can manage titration with an approved vaporiser. Do not smoke it.
Avoid any item labelled for smoking, sold by weight in unmarked packaging or offered without a batch number.

Red flags: when an item or vendor is outside the regulated scheme

Stop and verify if you encounter any of these:

The item is sold without a prescription.
The seller is not a licensed pharmacy.
The packaging lacks a batch number, expiry date or licence holder name.
The item is marketed as “raw herb”, “organic bud” or “natural medicine” without GMP certification.
The seller claims the item is legal because it contains CBD or is “hemp-derived”.
You are offered cannabis for smoking, not vaporisation.
The vendor suggests home cultivation is permitted for patients.

Where to go next

Medsafe medicinal cannabis pages: The official list of approved items and regulatory updates.
NZ Formulary: Prescribing monographs and clinical guidance for practitioners.
Healthify: Patient-facing explanations of medicinal cannabis and the prescription route.
Your medical practitioner: The only person who can start a prescription under the scheme.